Braveheart Bio's $503.5m post-IPO war chest backs three-trial heart drug plan

Braveheart Bio ended the third quarter with $503.5m in cash, a position it says will cover operating costs until 2029. The balance follows the company's initial public offering in August and gives it a multi-year runway while it develops BHB-1893, its cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM).

The company set out its pipeline plans alongside the 10 November results. Its Phase 3 LIONHEART-HCM study is already recruiting. Braveheart says it has received FDA input that backs a fixed-dose Phase 2b trial, which it plans to start in the first half of 2027. It also intends to open a Phase 3 trial, NOBLEHEART-HCM, in non-obstructive HCM within that window. No design details for either study were available.

Braveheart also presented 52-week open-label data on BHB-1893 at the American Heart Association 2026 meeting, saying no severe or serious adverse events occurred while patients were on treatment. The information available does not include patient numbers or efficacy endpoints, and uncontrolled, open-label studies cannot be read as evidence from randomised comparisons.

As context, myosin inhibitors for HCM are a class that already has an approved product in the obstructive form of the disease. The planned non-obstructive study would extend Braveheart's ambitions into a broader patient group, but the company has given no figures on market size, pricing or revenue expectations.